To include your compound in the COVID-19 Resource Center, submit it here.

APC 2059: Phase II

AXPH said that data from 53 evaluable patients (of a total of 56) in an open label

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE